Table 3 Correlation between survival and participants’ characteristics

Age

 ≤ 24 (n = 1)

0.00

1 (100%)

21.059

0.0001

 25–44 (n = 18)

0.00

18 (100%)

 45–65 (n = 40)

16 (40%)

24 (60%)

 ≥ 65 (n = 11)

9 (81.8%)

2 (18.2%)

Gender

 Male (n = 36)

12 (33.3%)

24 (66.7%)

0.183

0.6

 Female (n = 34)

13 (38.2%)

21 (61.8%)

Orbital involvement

 Involved (n = 34)

21 (61.8%)

13 (38.2%)

19.541

 < 0.0001

 Not involved (n = 36)

4 (11.1%)

32 (88.9%)

Stage

 Stage 1 (n = 7)

0.00

7 (100%)

21.375

 < 0.0001

 Stage 2 (n = 29)

4 (13.8%)

25 (86.2%)

 Stage 3 (n = 25)

14 (56%)

11 (44%)

 Stage 4 (n = 9)

7 (77.8%)

2 (22.2%)

Comorbidity

 Ongoing DM (n = 33)

13 (39.4%)

20 (60.6%)

10.136

0.07

 Denovo DM (n = 26)

7 (26.9%)

19 (73.1%)

 CKD (n = 4)

1 (25%)

3 (75%)

 AML (n = 3)

3 (100%)

0.00

 Kidney transplantation (n = 1)

1 (100%)

0.00

 COVID-19 + Systemic steroid (n = 3)

0.00

3 (100%)

Organism

 Mucor (n = 50)

17 (34%)

33 (66%)

4.462

0.2

 Aspergillus (n = 4)

3 (75%)

1 (25%)

 Both (n = 3)

0.00

3 (100%)

 No data (n = 13)

5 (38.5%)

8 (61.5%)

Time of treatment^a

 ≤ 7 days (n = 39)

23 (59%)

16 (41%)

20.813

 < 0.0001

 8–14 days (n = 28)

2 (7.1%)

26 (92.9%)

 15–21 days (n = 3)

0.00

3 (100%)